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1. Introduction 
Hashimoto’s thyroiditis (HT) is an autoimmune disease with genetic background. It is also 
named as autoimmune thyroiditis or chronic lymphocytic tiroiditis. Hashimoto's thyroiditis 
is the most common cause of thyroid diseases in children and adolescents and it is also the 
most common cause of acquired hypothyroidism with or without goiter. Hashimoto’s 
thyroiditis was first described in 1912 by Hakura Hashimoto in a series of patients with 
diffusely enlarged, firm thyroid glands with distinct pathologic features, classified as 
chronic lymphocytic thyroiditis (1). The characteristic histologic features include diffuse 
lymphocytic infiltration, atrophic follicles, well-developed germinal centers, and fibrosis. 
Hashimoto's thyroiditis is the most important cause of hypothyroidism in children and 
adolescents. In an American population with age between 11 and 18 years, five new cases were 
detected out of 1,000 adolescents screened every year. It is more common among girls, varying 
from 4:1 to 8:1 depending on the geographical region. Although the disease can be seen before 
three years of age, it is usually seen after six years of age and its peak ages are 10 and 11 years 
(2). The prevelance of Hashimoto's thyroiditis between 6-18 years old is 3% in Japan. Thirty-
40% of the cases have familial history of thyroid disease. It occurs far more often in women 
than in men (between 10:1 and 20:1), and is most prevalent between 45 and 65 years old. 
Autoimmune thyroid disease (AITD) has two clinical forms: a goitrous form more common 
in young age groups, in whom goiter may be the only clinical expression (3), often referred 
to as classical Hashimoto's disease, and an atrophic one often called atrophic thyroiditis (4). 
Both are characterized by circulating thyroid autoantibodies and varying degrees of thyroid 
dysfunction, differing only by the presence or absence of goiter. 
The prognosis is not known very well, and studies reporting about long-term outcome of 
the disease are scarce (3,5). Thyroid function tests show variations at the time of diagnosis; 
mostly euthyroid or hypothyroid and rarely hyperthyroid. Hypothyroidism is thought to be 
a permanent sequelae of HT. Patients with overt hypothyroidism may have been 
recommended lifelong levothyroxine (LT4) therapy but it should be checked after puberty if 
LT4 therapy is still necessary or not.  
2. Etiology 
Hashimoto’s thyroiditis is influenced by both genetic and environmental factors (6). Family 
and twin studies support the evidence for genetic susceptibility (7-9). Dittmar et al. (10) have 
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shown the increased familial risk especially for the first-degree relatives and females.  In 
particular, children and siblings of patients with Hashimoto’s thyroiditis had a 32-fold and 
21-fold increased risk, respectively, for developing immunthyroiditis. In comparison, the 
risk for developing Graves’ disease has been enhanced 7-fold in both children and siblings 
(10). The high prevalence of AITD in first degree, foremost female, and relatives of patients 
with AITD demonstrates the importance of family history for developing AITD. This genetic 
susceptibility shows necessity of familial regular screening. 
Candidate gene analysis, whole-genome linkage screening, genome-wide association 
studies, and whole-genome sequencing are the major technologies that have advanced this 
field, leading to the identification of at least seven genes whose variants have been 
associated with AITD (11). Using these techniques, 6 AITD susceptibility genes have been 
identified and confirmed, HLA-DR, CD40, CTLA-4, PTPN22, Thyroglobulin (Tg) and TSH 
receptor. The AITD susceptibility genes identified so far can be divided into two broad 
groups: immune modulating genes and thyroid specific genes. The first group includes the 
HLA-DR, CD40, CTLA-4, and PTPN22 genes, while the second group includes the Tg and 
TSH reseptor genes (12). In our previous study, we have studied an association of three 
polymorphic markers of CTLA-4 gene, namely, C(-318)T, A49G, and (AT)n dinucleotide 
repeat, which is known the relation with Graves' disease and we reported that A49G 
polymorphism may increase the susceptibility for Hashimoto’s thyroiditis (13). 
It is clear that additional genes contribute to the genetic susceptibility to AITD, as well as to 
the different phenotypes of AITD, disease severity, and, possibly,  response to therapy but 
HLA-DR and Tg genes have stronger relation with HT than the others (14). 
Several environmental and non-genetic triggers have been implicated in the etiology of HT. 
These include smoking, stress, iodine excess, medications, bacterial, and viral infections, 
irradiation, pollutants, and pregnancy. The mechanisms by which certain environmental 
agents induce thyroid disease could involve interference with thyroid function, direct toxic 
effects on thyrocytes, or immune stimulation, as well as other effects. It is often difficult to 
directly link an environmental exposure with thyroid autoimmunity, as disease may be 
associated with a combination of factors and can manifest over a long period of time. When 
an environmental exposure triggers HT in individuals with pre-existing thyroid 
autoantibodies, this may indicate gene-environment interaction, as the presence of thyroid 
antibodies is usually a surrogate marker of genetic susceptibility (15). 
3. Iodine 
Iodine is one of the most important precipitants of thyroid dysfunction. Although essential 
for normal thyroid function, excess iodine supplementation can be associated with the onset 
of thyroid autoimmunity. Potential mechanisms by which iodine can induce autoimmunity 
in the thyroid include direct stimulation of immune responses to the thyroid, increased 
immunogenicity of highly iodinated Tg, and direct toxic effects of iodine on thyrocytes via 
free oxygen radicals generation (16). A few studies have demonstrated increased incidence 
of autoimmune thyroiditis in regions where iodine consumption is high according to 
regions with low consumption (16-18). 
4. Selenium 
Selenium is a trace element that plays an essential role in thyroid hormone synthesis, 
because two enzymes involved in thyroid hormone production are selenoproteins: the 
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deiodinases and glutathione peroxidase. Selenium influences the immune system probably 
by enhancing plasma glutathione peroxidase and thioredoxin reductase activity and by 
decreasing toxic concentrations of hydrogen peroxide and lipid hydroperoxides, resulting 
from thyroid hormone synthesis (19,20). A deficit of selenium results in increased 
intrathyroidal levels of hydrogen peroxide, which possibly increase the activity and 
immunogenicity of Thyroid Peroxidase (TPO) (21). Low selenium blood levels cause 
increased thyroid volume and thyroid hypoechogenicity, a marker for lymphocytic 
infiltration (22). 
5. Medication 
Several medications may play a role in the development of HT. Interferon-α, interleukin-2, 
lithium, amiodarone, and highly active antiretroviral therapy are the agents most commonly 
associated with thyroid dysfunction (23). 
6. Infections 
Several infections have been implicated in the pathogenesis of HT including Helicobacter 
pylori, Borrelia burgdorferi, Yersinia enterocolitica, Coxsackie virus, and retroviruses. 
Furthermore, recent studies but not all have substantiated a strong association between HT 
and HCV (24,25). 
Seasonal and geographic variations also support infection as a trigger of HT (11,23). Various 
mechanisms have been proposed to explain induction of autoimmunity by infection but it 
seems that three possibilities may be important in individuals susceptible to developing 
autoimmune disease: molecular mimicry (perhaps to retroviruses); polyclonal T cell 
activation (by an endogenous superantigen or an infecting organism); and MHC class II 
antigen induction (26). Although infections may promote HT, they can also be partially 
protective, as suggested by the hygiene hypothesis. According to this hypothesis, the 
immune system builds tolerance to repeated infectious exposures, and this may explain a 
lower prevalence of thyroid antibodies in those of lower socioeconomic class (27). 
6.1 Environmental toxins 
Many environmental pollutants, such as polyaromatic hydrocarbons, perfluorinated 
chemicals, phthalates, and bisphenol A, have been shown to be toxic to thyroid cells and 
promote the onset of HT (15). These chemicals are widely used in various industrial and 
consumer products and may specifically have thyroid-disrupting properties (28,29). 
Polyaromatic hydrocarbons, including polychlorinated biphenyls and polyhalogenated 
biphenyls, are organic compounds produced from coal and found in air and water, and they 
can possibly trigger thyroiditis. Polyhalogenated biphenyls are commonly used compounds 
in products including adhesives, lubricants, and flame retardants, while polychlorinated 
biphenyls are found in plasticizers. A high prevalence of hypothyroidism was observed in 
individuals exposed to polyhalogenated biphenyls with an associated elevation in 
antimicrosomal antibodies and anti-Tg antibodies (30). In view of the evidence that many of 
these chemicals can interfere with thyroid function, there is a growing concern about their 
effects on neurological development during embryonic life (15,29). Exposure during  
pregnancy, for example, which itself is a risk factor for HT, can have hazardous effects on 
the developing fetus in which normal thyroid hormone levels are crucial for normal growth 
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and brain development. It is important, therefore, to be aware of environmental triggers of 
HT and to monitor thyroid functions closely in susceptible women during pregnancy 
(15,23). 
7. Pathogenesis 
The activation of CD4 T-lymphocytes specific for thyroid antigens is believed to be the first 
step in pathogenesis. Once activated, self-reactive CD4 T cells recruit cytotoxic CD8 T cells 
as well as autoreactive B cells into the thyroid. T cells play a crucial role in disease 
pathogenesis by reacting with thyroid antigens and secreting inflammatory cytokines. 
Besides the others, mutations in the Tg gene and CTLA-4 are associated with HT (31,32). 
The three main targets of thyroid antibodies are Tg, TPO, and the TSH receptor. It is 
believed that these autoantibodies are secondary to thyroid follicular cell damage induced 
by T cells Anti-TPO antibodies have been shown to inhibit the activity of the enzyme in 
vitro, but direct cytotoxicity by CD8 T cells is believed to be the main mechanism of 
hypothyroidism in vivo. Thyroid peroxidase is the major autoantigen and autoantibodies to 
TPO are closely associated with disease activity. Although this has not been proven in 
children Anti-TSH receptor antibodies of the blocking type may contribute to 
hypothyroidism in a minority of adult patients with the atrophic form of autoimmune 
thyroiditis. Histologically, HT is characterized by diffuse lymphocytic infiltration with 
occasional germinal centers. Thyroid follicles may be reduced in size and contain sparse 
colloid. Individual thyroid cells are often enlarged with oxyphilic cytoplasm. In contrast, the 
gland of atrophic autoimmune thyroiditis is small, with lymphocytic infiltration and fibrous 
replacement of the parenchyma (5). 
8. Clinical manifestation 
Hashimoto’s thyroiditis is one of the most common organ specific autoimmune diseases 
(33). Weetman (34) reported clinical HT prevalence rate at 1 in 182 or 0.55% in the US. In the 
UK, Tunbridge et al (35) reported an overall HT prevalence of 0.8%. However, diagnosis 
based fine needle aspiration biopsy study; the cytology of HT seems to be much more 
prevalent, at 13.4% (36). This difference may be partially explained by the fact that for 
diagnosing clinical HT, abnormally elevated TSH, low thyroid hormones (34,35) and the 
confirmatory presence of thyroid autoantibodies are usually accounted for. 
The most common clinical manifestations are goiter and hypothyroidism related findings. 
The goiter may appear insidiously and may be small or large. In most patients, the thyroid is 
diffusely enlarged, firm, and nontender. In about 30% of patients, the gland is lobular and 
may seem to be nodular (37). Most of the affected children are clinically euthyroid and 
asymptomatic; some may have symptoms of pressure in the neck. Some children have 
clinical signs of hypothyroidism, but others who appear clinically euthyroid have laboratory 
evidence of hypothyroidism. A few children have manifestations suggestive of 
hyperthyroidism, such as nervousness, irritability, increased sweating, and hyperactivity, 
but results of laboratory studies are not necessarily those of hyperthyroidism (37). In one 
study from iodine replete area with 140 patients with HT, the most common complaint was 
goiter (55%). Upon admission, 18.6% of patients had complaints related to hypothyroidism 
(7.4% growth retardation, 4.9% weight gain and 6.3% other complaints related to 
hypothyroidism). Eighteen patients (11.1%) were diagnosed incidentally upon detection of 
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goiter during routine examination (38). Staii et al. reviewed 761 patients for which 
ultrasound guided thyroid fine needle aspiration biopsy were performed for nodule. The 
HT cohort consisted of 102 (13.4%) patients (659 out of 761 did not have cytological 
Hashimoto’s diagnosis) for which 46 (6%) were identified as having clinical disease (i.e. 
diagnosed hypothyroid on thyroid hormone replacement and with cytological Hashimoto’s 
diagnosis), 9 (1.2%) as having subclinic hypothyroidism and 47 (6.2%) as having euthyroid 
autoimmunity (36). Occasionally, the disorder may coexist with Graves’s disease. 
Ophthalmopathy may occur in lymphocytic thyroiditis in the absence of Graves’s disease. 
Hashimoto’s encephalopathy is a rare condition and the estimation of incidence and 
prevalence is difficult. One prospective study examining cases of unexplained 
encephalopathy that had detectable antithyroid antibodies, estimated a prevalence of 
2.1/100 000 subjects (39). Adequate information is not available about the frequency of 
Hashimoto’s encephalopathy in children (40). The clinical picture of a relapsing and 
remitting encephalopathy in a female characterised by seizures, stroke-like episodes, 
neurological signs such as myoclonus and tremor, cognitive disturbance and hallucinations, 
and other psychotic symptoms is highly suggestive of Hashimoto’s encephalopathy (41). 
Normal routine investigations, nonspecific neuroimaging and CSF findings (apart from 
elevated protein), and encephalopathic EEG can be supportive of the diagnosis. Thyroid 
hormone studies are not helpful, but may identify subclinical thyroid dysfunction (41). 
Detection of antithyroid (in particular anti-TPO) antibodies confirms the diagnosis. As anti-
TPO antibodies are detected in as many as 10 % of the general population, (42) high titres 
(usually over 100-fold normal (43)) of these antibodies in conjunction with the clinical 
features of Hashimoto’s encephalopathy are necessary before a diagnosis can be made. 
Thyroid antibody levels should be measured even in the setting of normal thyroid function 
and the diagnosis of Hashimoto encephalopathy has to be considered in patients with Down 
syndrome who present with rapid cognitive decline, particularly in association with 
myoclonus and an abnormal EEG result (44). Corticosteroid responsiveness can also support 
the diagnosis (45). 
9. Related disorders 
HT may be the initial presentation of an autoimmune polyglandular syndrome, and the 
possibility of coexisting autoimmune diseases such as type I diabetes, celiac disease, 
Addison’s disease, and pernicious anemia must be addressed by the past medical history 
(46). In a study performed on 268 children with type I diabetes mellitus, the percentage of 
those who presented with circulating thyroperoxidase and Tg antibodies was significantly 
higher than those with celiac disease (47). In another study performed in Bratislava, 40-50% 
of patients with different types of diabetes had autoimmune thyroiditis (48). The incidence 
of histologic findings of autoimmune thyroid disease in diabetic patients increases with age 
(49). Several other studies have confirmed the coincidence of autoimmune thyroiditis and 
latent or overt diabetes (50) and relatives of patients with type I diabetes have an increased 
incidence of HT (51). In a recent study, genetic susceptibility between autoimmune 
thyroiditis and diabetes was investigated among 448 individuals. Three loci in 
chromosomes 2q, 6p and Xp were identified (52). 
Hashimoto’s thyroiditis sometimes may be associated with connective tissue, cutaneous, 
hematologic (pernicious anemia, idiopathic thrombocytopenic purpura), gastrointestinal 
(autoimmune liver disease, celiac disease), genetic (autoimmune polyglandular syndrome 
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type II/III, ovarian failure, Down syndrome, Klinefelter’s syndrome, Turner’s syndrome), 
infectious (Hepatitis C infection), neurologic (Miller Fisher syndrome, Guillain-Barre´ 
syndrome, multiple sclerosis, myasthenia gravis) and renal diseases (minimal change 
glomerular disease) (53). 
The coexistence of papillary thyroid carcinoma and HT is not known exactly, but it is 
reported to range from 10% to 58% in various studies (54,55). The prevalence of HT in 
patients with papillary thyroid carcinoma has been reported to be significantly higher than 
with benign thyroid tumours (56). Patients with HT are suggested to be at higher risk for 
papillary thyroid carcinoma compared with patients without HT (57) 
10. Laboratory findings 
Although the level of TSH may be slightly or even moderately raised in some individual’s 
thyroid function tests are often normal, termed subclinical hypothyroidisms (37). In a study 
from iodine-replete area, twenty-four patients (21%) were euthyroid, 48 (42%) had 
compensated hypothyroidism, and 42 (37%) had hypothyroidism (including two patients 
with transient hyperthyroidism reversed to hypothyroidism within weeks). There was no 
difference in clinical symptoms of hypothyroidism by thyroid status, except for a higher rate 
of constipation in the hypothyroid group (38). The fact that many children with lymphocytic 
thyroiditis do not have elevated levels of TSH indicates that the goiter may be caused by the 
lymphocytic infiltrations or by thyroid growth-stimulating immunoglobulins. 
In normal individuals, positive anti-TPO were detected in 13.0 ± 0.4%, and positive Anti-Tg 
was detected in 11.5 ± 0.5%. The prevalence of positive antibodies was lower in the disease-
free population: Anti-TPO, 11.3 ± 0.4% and Anti-Tg, 10.4 ± 0.5%. The prevalence of positive 
Anti-TPO and positive Anti-Tg in the total and disease-free population was higher in 
females than males (P< 0.001) and increased with age, especially among females. 
Approximately 18% of the disease-free population had detectable Anti-Tg or Anti-TPO of 
those with positive Anti-Tg, 69.9% also had positive Anti-TPO; and of those with positive 
Anti-TPO, 54.5% also had positive Anti-Tg. Anti-TPO was positive alone in 4.4%, and Anti-
Tg was positive alone in 3.4%. Anti-TPO and Anti-Tg were detected together in 6.9% (59). 
Almost all young children with HT have serum antibody titres to TPO, but the anti-Tg test 
for thyroid antibodies is positive in fewer than 50%. Antibodies to TPO and Tg are found 
equally in adolescents with HT. When both tests are used, approximately 95% of patients 
with thyroid autoimmunity are detected. Levels in children and adolescents are lower than 
those in adults with HT, and repeated measurements are indicated in questionable instances 
because titres may increase later in the course of the disease (37). Results about decreasing 
Anti-TPO under LT4 treatment have been found variable with 10% and 90% after a follow-
up of 6 to 24 months (60,61). Decreasing Anti-TPO under LT4 treatment appears to depend 
on time, a 45 % decrease after 1 year and a 70% decrease after 5 years (62). 
11. Imaging 
Thyroid ultrasonography is a useful tool to support the diagnosis, and classical sonographic 
findings are present in 20-95% of affected individuals (63). Furthermore, their presence is 
related to subclinical hypothyroidism and levels of thyroid autoantibodies (64,65), and 
ultrasonography has been used for the follow-up of patients (66). Thyroid ultrasonography 
is usually heterogeneous because of fibrosis and hypoechogenic areas, it is not necessary for 
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diagnosis but it is recommended  to confirm the presence of a thyroid nodule, solitary or 
multiple nodule can be detected both hypothyroid or euthyroid patients. During disease 
progression, reduced echo levels develop gradually, reflecting either reduction of colloid 
content and increased intrathyroidal blood flow or lymphocytic tissue infiltration, which 
induces diffuse fibrosis (64). The appearance of thyroid gland on ultrasonography may be 
normal at diagnosis, but characteristic changes evolve over time. Vlachopapadopoulou et al. 
studied 105 children, the time needed for 30%, 50%, and 70% of children to demonstrate an 
abnormal thyroid sonographic pattern has been detected 4, 7, and 14 months, respectively. 
Important factors accelerating sonographic changes have been demonstrated as goiter, 
hypothyroidism, and seropositivity for both anti-TPO and anti-Tg autoantibodies (67). 
12. Diagnosis 
Hashimoto’s thyroiditis is diagnosed based on findings of seropositivity for Tg 
autoantibodies and/or TPO autoantibodies, accompanied by at least one of the following: 
abnormal thyroid function; enlarged thyroid gland; morphological changes on thyroid 
ultrasound. If anti-TPO antibodies are absent, less common etiologies of primary 
hypothyroidism should be considered for example transient hypothyroidism due to 
postsubacute thyroiditis, hypothyroidism related to external irradiation (69) and 
consumptive hypothyroidism due to the inactivation of thyroid hormone by the 
paraneoplastic expression of type III iodothyronine deiodinase, mostly in vascular tumors 
(70). 
The typical patient with hypothyroidism secondary to HT has an elevated TSH, a low fT4, 
and positive anti-TPO antibodies. In early stages of the disease, TSH may be normal and 
anti-TPO antibodies may be positive with or without goiter. Later, TSH elevation becomes 
modest (5-10 IU/mL) with a normal fT4 (biochemical or subclinical hypothyroidism). Up to 
90% of patients with hypothyroidism secondary to HT have positive anti-TPO antibody (46). 
If HT is suggested and thyroid autoantibodies are negative, they should be controlled later. 
It is possible to raise in follow-up. 
13. Treatment 
Most of these patients are asymptomatic, but studies in the adult population suggest that 
individuals with the combined risk factors of TSH level above the normal limit and positive 
thyroid antibodies (anti-Tg or anti-TPO) are at high risk for progression to overt 
hypothyroidism. For this reason, thyroid hormone replacement is recommended in all 
patients with TSH values >10 IU/mL or with TSH values >5 IU/mL in combination with 
goiter or thyroid autoantibodies (71). Levothyroxine is the replacement therapy of choice. 
There are almost no adverse reactions; its good intestinal absorption and its long half life of 
5-7 days allow oral administration once a day. Although very rare, the development of 
pseudotumor cerebri associated with the initiation of LT4 has been described in a few 
school-age children (72). Alternatively, a starting dose can be estimated based upon the 
patient’s age and ideal body weight (73). The medication’s long half-life insures a gradual 
equilibration over the course of 5 – 6 weeks, and dosing should be individualized based on 
biochemical monitoring (73). TSH normalization (0.5-2 micro IU/mL) is the goal of 
replacement. This will usually be associated with an fT4 in the upper half of the normal 
range. Thyroid function tests should be obtained about 6-8 weeks after the beginning or next 
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adjustment of the LT4 dosage. Very high TSH levels at diagnosis can be associated with 
thyrotroph hypertrophy and gradual suppression over the first year of treatment (74,75). 
Once biochemical euthyroidism has been achieved, TSH can be monitored every 4-6 months 
in the growing child and yearly up to the attainment of final height. If poor compliance is 
suspected as the cause of treatment failure, fT4 should be measured. 
Levothyroxine should be administered at least 20 min, before eating or ingestion of any 
medication known to impair its absorption, such as calcium and iron supplements, 
sucralfate, potassium-binding resins, antacids containing aluminium, and bile-acids binding 
resins. All other medications should be checked for interactions, particularly with 
antidepressants and seizure medications. 
Growth and sexual development should be followed systematically as in any pediatric 
patient. Parents of children with HT should be advised that the hypothyroidism is likely to 
be permanent and monitoring of thyroid function for all patients should be life long. The 
prognosis for recovering lost linear growth depends on the duration of the hypothyroidism 
as well as the age at which treatment is started. If hypothyroidism is long-standing, thyroid 
replacement will not recover all lost stature. Similarly, if the diagnosis is made around 
puberty, there may be limited time for recovering the growth spurt before attaining final 
height. If the onset of childhood hypothyroidism occurs after age 3 years, no permanent 
intellectual damage or neurologic deficit is probable. 
Surgical therapy for HT most commonly is recommended in case of malignancy or for relief 
of compressive symptoms in patients who develop a nodular or diffuse goiter. Patients may 
have an associated firm nodule in the thyroid gland and the thyroid gland may be adherent 
to adjacent structures with associated enlarged lymph nodes, mimicking thyroid cancer. 
Large goiter with HT can cause local compressive symptoms such as dysphagia, coughing 
or choking spells, dyspnea, and hoarseness that may require surgery for relief of 
compression (76). Thirty-two (15%) of 216 patients with HT were referred with thyroid 
enlargement and compressive symptoms; 25 (78%) had an associated nodule and 12 (38%) 
had retrosternal extension. Symptom resolution occurred in 30 (94%) and improvement 
occurred in 2 (6%) patients after total thyroidectomy in 21 (66%) and thyroid lobectomy in 
11 (34%) patients. The only complication was transient hypocalcemia in 12 (38%) patients. 
One patient had an incidental thyroid lymphoma (77). 
14. Follow-up 
Although a percentage of patients acquire hypothyroidism gradually within months or 
years, most children who are euthyroid at presentation remain euthyroid. Over several 
years, about half of children with subclinical hypothyroidism revert to euthyroidism, while 
the other half develops overt hypothyroidism. In a multicentre study Radetti et al. 
investigated the outcome of euthyroid children with HT and showed that 64.8% of them 
remained euthyroid, 9.5% progressed to subclinical hypothyroidism and 25.7% to overt 
hypothyroidism after 5 years (78). 
Few studies have examined the spontaneous evolution of the disease (80,81). A recent Italian 
retrospective study described the outcome of 160 children affected with HT followed for up 
to 32.6 years in 20 pediatric endocrine clinics (78). In compatible with other reports (80,81), 
TSH concentrations have showed large fluctuations overtime. The presence of associated 
diseases has not worsened the prognosis, because at the end of the follow-up no difference 
has been found in the frequency of abnormally elevated TSH between the groups with or 
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without associated diseases. In agreement with previous findings in children (82,83) and in 
contrast with adults (84), the TSH level at baseline was not a useful marker to predict 
disease evolution. Both thyroid antibodies were significantly higher at the last visit in the 
group with deteriorating thyroid function; however, whereas anti-Tg antibodies were 
already higher at baseline, anti-TPO antibodies increased progressively with time. This 
finding suggests that anti-TPO antibodies might represent a marker of deteriorating thyroid 
function, in agreement with a previous report showing a good correlation between anti-TPO 
antibodies levels and lymphocytic infiltration of the gland (85). The evaluation of patients, 
according to their final outcome, revealed that subjects with deteriorating thyroid function 
had significantly higher anti-Tg antibodies, TSH concentrations, and greater thyroid volume 
at presentation. Nonetheless, these findings were not helpful in individual patients. On the 
other hand, it should be remarked that at 5 years of followup, more than 50% of the patients 
remained or became euthyroid. Ikemoto investigated 199 adult patients with HT and 
reported a recovery rate from hypothyroidism of 40% within 10.5 years of follow-up. In the 
same study elevated titres for thyroid autoantibody, age above 50 years and the presence of 
a stony-hard goitre were the best predictive factors for permanent hypothyroidism (86). In 
children the presense of predictive factors for permanent hypothyroidism are controversial. 
In the current study, initial TSH levels and thyroid volume at presentation, duration of 
levothyroxine therapy and anti-TPO Ab titre were not predictive for permanent 
hypothyroidism (79). Previously it was shown that iodine supplementation is associated 
with increased incidence of HT (87,88). In addition, it has been suggested that patients with 
HT are prone to develop hypothyroidism following iodine administration. Daily iodine 
supplementation over 1 mg has been shown to potentially contribute to underlying thyroid 
pathology in those with HT or Graves’ disease. Exacerbation of nodularities in euthyroid 
individuals may occur if daily intake exceeds 20 mg iodine or iodide (89,90). 
It is usually offered a trial of LT4 therapy to adolescents, after the completion of growth and 
puberty. Thyroid function is retested 6–8 weeks after the stop of medication, to determine if 
hypothyroidism is permanent and potentially restart therapy. 
15. References 
[1] Hashimoto H. Zur kenntniss der lymphomatosen veranderung der schilddruse (struma 
lymphomatosa). Arch Klin Chir 1912; 97: 219-248. 
[2] Setian NS. Hypothyroidism in children: diagnosis and treatment. Jornal de Pediatria 
2007; 83: 209-216. 
[3] Rallison ML, Dobyns BM, Keating FR, Rall JE, Tyler FH. Occurrence and natural history 
of chronic lymphocytic thyroiditis inchildhood. Journal of Pediatrics 1975; 86: 675-
682. 
[4] Brown RS: Thyroid disease in infancy, childhood and adolescence. In: Braverman LE 
(ed). Contemporary Endocrinology. Totowa, Humana Press, 1997, 81-102. 
[5] Dayan CM, Daniels GH. Chronic autoimmune thyroiditis. New England Journal of 
Medicine 1996; 335: 99-107. 
[6] Weetman AP. Autoimmunity and endocrinology. Exp Clin Endocrinol Diabetes 1999; 
107: 63-66.    
[7] Villanueva R, Greenberg DA, Davies TF, Tomer Y. Sibling recurrence risk in 
autoimmune thyroid disease. Thyroid 2003; 13: 761-764. 
www.intechopen.com
 
Autoimmune Disorders – Current Concepts and Advances from Bedside to Mechanistic Insights 
 
36
[8] Hall R, Stanbury JB. Familial studies of autoimmune thyroiditis. Clin Exp Immunol 1967; 
2: 719-725. 
[9] Segni M, Wood J, Pucarelli, Toscano V, Toscano R, Pasquino AM. Clustering of 
autoimmune thyroid diseases in children and adolescents: a study of 66 families. J 
Ped Endocrinol Metab 2001; 14: 1271-1297. 
[10] Dittmar M, Libich C, Brenzel T, Kahaly GJ. Increased Familial Clustering of 
Autoimmune Thyroid Diseases. Horm Metab Res 2011; 43: 200-204. 
[11] Yaron T, Amanda H. The etiology of autoimmune thyroid disease: A story of genes 
and environment. Journal of Autoimmunity 2009; 32: 231-239. 
[12] Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting 
and reporting linkage results. Nat Genet 1995; 11: 241-247. 
[13] Yeşilkaya E, Koç A, Bideci A, Camurdan O, Boyraz M, Erkal O, Ergun MA, Cinaz P. 
CTLA-4 gene polymorphisms in children and adolescents with autoimmune 
thyroid diseases. Genet Test 2008; 12: 461-464. 
[14] Deirdre CE, Alia H, Yaron T, Cutting E. The Etiology of Autoimmune Thyroid 
Diseases. Curr Opin Endocrinol Diabetes Obes 2010; 17: 437-439. 
[15] Brent GA. Environmental exposures and autoimmune thyroid disease. Thyroid 2010; 
20; 755-761. 
[16] Papanastasiou L, Vatalas L, Koutras DA, Mastorakos G. Thyroid autoimmunity in the 
current iodine environment. Thyroid 2007; 17: 729-739. 
[17] Teng W, Shan Z, Teng X, Guan H, Li Y, Teng D, Jin Y, Yu X, Fan C, Chong W, Yang F, 
Dai H, Yu Y, Li J, Chen Y, Zhao D, Shi X, Hu F, Mao J, Gu X, Yang R, Tong Y, Wang 
W, Gao T, Li C. Effect of iodine intake on thyroid diseases in China. N Engl J Med 
2006; 354: 2783-2793. 
[18] Doufas AG, Mastorakos G, Chatziioannou S, Tseleni-Balafouta S, Piperingos G, Boukis 
MA, Mantzos E, Caraiskos CS, Mantzos J, Alevizaki M, Koutras DA. The 
predominant form of non-toxic goiter in Greece is now autoimmune thyroiditis. 
Eur J Endocrinol 1999; 140: 505-511. 
[19] Beckett GJ, Arthur JR. Selenium and endocrine systems. J Endocrinol 2005; 184: 455-
465. 
[20] Duntas LH. The role of selenium in thyroid autoimmunity and cancer. Thyroid 2006; 
16: 455-460. 
[21] Caturegli P, Kimura H, Rocchi R, Rose NR. Autoimmune thyroid diseases.  Curr Opin 
Rheumatol 2007; 19: 44-48. 
[22] Klecha AJ, Barreiro Arcos ML, Frick L, Genaro AM, Cremaschi G. Immune-Endocrine 
Interactions in Autoimmune Thyroid Diseases. Neuroimmunomodulation 2008; 15: 
68-75. 
[23] Tanda ML, Piantanida E, Lai A, Lombardi V, Dalle Mule I, Liparulo L, Pariani N, 
Bartalena LThyroid autoimmunity and environment. Horm Metab Res 2009; 41: 
436-442. 
[24] Menconi F, Hasham A, Tomer Y. Environmental triggers of thyroiditis: Hepatitis C and 
interferon-α J Endocrinol Invest 2011; 34: 78-84. 
[25] Mori K, Yoshida K. Viral infection in induction of Hashimoto's thyroiditis: a key player 
or just a bystander? Curr Opin Endocrinol Diabetes Obes 2010; 17: 418-424. 
[26] Tomer Y, Davies TF. Infections and autoimmune endocrine disease. Bailli eres Clin 
Endocrinol Metab 1995; 9: 47-70. 
[27] Desailloud R, Hober D. Viruses and thyroiditis: an update. Virol J 2009; 12: 6: 5. 
www.intechopen.com
 
Hashimoto's Thyroiditis in Children and Adolescents 
 
37 
[28] Andrade LJ, Atta AM, D'Almeida Junior A, Paraná R Thyroid dysfunction in hepatitis 
C individuals treated with interferon-alpha and ribavirin—a review. Braz J Infect 
Dis 2008; 12:144-148. 
[29] Boas M, Main KM, Feldt-Rasmussen U. Environmental chemicals and thyroid function: 
an update. Curr Opin Endocrinol Diab Obes 2009; 16: 385-391. 
[30] Bahn AK, Mills JL, Snyder PJ, Gann PH, Houten L, Bialik O, Hollmann L, Utiger RD. 
Hypothyroidism in workers exposed to polybrominated biphenyls. N Engl J Med 
1980; 302: 31-33. 
[31] Ban Y, Greenberg DA, Concepcion E, Skrabanek L, Villanueva R, Tomer Y. Amino acid 
substitutions in the thyroglobulin gene is associated with susceptibility to human 
and murine autoimmune thyroid disease. Proc Natl Acad Sci USA 2003; 100: 15119-
15124. 
[32] Ban Y, Davies TF, Greenberg DA, Kissin A, Marder B, Murphy B, Concepcion ES, 
Villanueva RB, Barbesino G, Ling V, Tomer Y. Analysis of the CTLA-4, CD28, and 
inducible costimulator (ICOS) genes in autoimmune thyroid disease. Genes Immun 
2003; 4: 586-593. 
[33] Hay ID. Thyroiditis: A clinical update. Mayo Clin Proc 1985; 60: 836-843. 
[34] Weetman AP: Thyroid disease. In: the Autoimmune Disease. Rose NR, Mackay IR 
(eds). 2006; 467-482. 
[35] Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, Evans JG, Young 
E, Bird T, Smith PA. The spectrum of thyroid disease in a community: The 
Whickham survey. Clin Endocrinol (Oxf) 1977; 7: 481-493. 
[36] Staii A, Mirocha S, Todorova-Koteva K, Glinberg S, Jaume JC. Hashimoto thyroiditis is 
more frequent than expected when diagnosed by cytology which uncovers a pre-
clinical state. Thyroid Research 2010, 3: 11.  
[37] Kliegman RM: Disorder of thyroid gland. In: Kliegman RM, Behrman RH, Jenson HB, 
Stanton BMD (eds). Nelson Textbook of Pediatrics. 18th ed, Sounders, 2007. 
[38] Demirbilek H, Kandemir N, Gonc E.N, Ozon A, Alikasifoglu A, and Yordam N. 
Hashimoto’s Thyroiditis in Children and Adolescent: A Retrospective Study on 
Clinical Epidemiological and Laboratory Properties of the Disease. Journal of 
Pediatric Endocrinology & Metabolism 2007; 20:1199-1205. 
[39] Ferracci F, Bertiato G, Moretto G. Hashimoto’s encephalopathy:  epidemiologic data 
and pathogenetic considerations. J Neurol Sci 2004; 217: 165-168. 
[40] Gayatri NA, Whitehouse WP.  Pilot survey of Hashimoto’s encephalopathy in children.  
Dev Med Child Neurol 2005; 47: 556-558. 
[41] Mocellin R, Walterfang M, Velakoulis D. Hashimoto’s Encephalopathy Epidemiology, 
Pathogenesis and Management. CNS Drugs 2007; 21: 799-811. 
[42] Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, 
Braverman LE. Serum TSH T(4),  and  thyroid  antibodies  in  the  United  States  
population (1988  to  1994):  National  Health  and  Nutrition  Examination Survey 
(NHANES III). J Clin Endocrinol Metab 2002; 87: 489-499. 
[43] Kothbauer-Margreiter I, Sturzenegger M, Komor J, Baumgartner R, Hess CW. 
Encephalopathy associated with Hashimoto thyroiditis. J Neurol 1996: 243: 585-593. 
[44] Brodtmann A. Hashimoto encephalopathy and Down syndrome.  Arch Neurol 2009; 
66: 663-666. 
www.intechopen.com
 
Autoimmune Disorders – Current Concepts and Advances from Bedside to Mechanistic Insights 
 
38
[45] Chong JY, Rowland LP.  What’s in a NAIM?  Hashimoto encephalopathy, steroid-
responsive encephalopathy associated with autoimmune thyroiditis, or 
nonvasculitic autoimmune meningoencephalitis? Arch Neurol 2006; 63: 175-176. 
[46] Cappa M, Bizzarri C, Crea F. Autoimmune Thyroid Diseases in Children. Journal of 
Thyroid Research 2010; 2011:675-703. 
[47] Körner A, Tóth-Heyn P, Dezsofi A, Veres G, Madácsy L, Arató A. Incidence of thyroid 
autoimmunity in children  with  type  1  diabetes  mellitus. Orv Hetil 2008; 149: 
4012-4406. 
[48] Schroner Z, Lazurova I, Petrovicova J. Autoimmune thyroid disease in patients with 
diabetes mellitus. Bratisl Lek List 2008; 109: 125-129. 
[49] Sharifi F, Ghasemi L, Mousavinasab N.  Thyroid  function  and  antithyroid antibodies  
in  Iranian  patients  with  type  1  diabetes  mellitus:  influence  of age and sex. Iran 
J Allergy Asthma Immunol 2008; 31: 6-10. 
[50] Araujo J, Brandão LA, Guimarães RL, Santos S, Falcão EA, Milanese M, Segat L, Souza 
PR, de Lima-Filho JL, Crovella S. Prevalence of autoimmune thyroid disease  and  
thyroid  dysfunction  in  young  Brazilian  patients  with  type  1 diabetes. Pediatr 
Diabetes 2008; 9: 272-276. 
[51] Payami H, Joe S, Thomas G. Autoimmune thyroid disease type 1 diabetic families. 
Genet Epidemiol 1989; 6: 137-143. 
[52] Villano MJ, Huber AK, Greenberg DA, Golden BK, Concepcion E, Tomer Y. 
Autoimmune  thyroiditis  and diabetes:  dissecting  the  joint  genetic  susceptibility  
in  a  large  cohort  of multiplex families. J Clin Endocrinol Metab 2009; 94: 1458-
1466. 
[53] Ai J, Leonhardt JM, Heymann WR.  Autoimmune thyroid diseases: Etiology, 
pathogenesis, and dermatologic manifestations.  J Am Acad Dermatol 2003; 48: 641-
659. 
[54] Tamimi DM.  The association between chronic lymphocytic thyroiditis and thyroid 
tumors. Int J Surg Pathol 2002; 10: 141-146. 
[55] Schäffler A, Palitzsch KD, Seiffarth C, Höhne HM, Riedhammer FJ, Hofstädter F, 
Schölmerich J, Rüschoff J. Coexistent thyroiditis is associated with lower tumour 
stage in thyroid carcinoma. Eur J Clin Invest 1998; 28: 838-844. 
[56] Okayasu I, Fujiwara M, Hara Y, Tanaka Y, Rose NR. Association of chronic 
lymphocytic thyroiditis and thyroid   papillary carcinoma.  A study of surgical   
cases among Japanese, and white and African Americans. Cancer 1995; 76: 2312-
2318. 
[57] Holm LE, Blomgren H, Lowhagen T. Cancer risks in patients with chronic lymphocytic 
thyroiditis. N Engl J Med 1985; 312: 601-604. 
[58] Saravanan P, Dayan CM. Thyroid autoantibodies. Endocrinology and Metabolism 
Clinics of North America 2001; 30: 315-337. 
[59] Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, 
Braverman LE. Serum TSH, T(4), and thyroid antibodies in the United States 
population (1988 to 1994): National Health and Nutrition Examination Survey 
(NHANES III). J Clin Endocrinol Metab 2002; 87: 489-499. 
[60] Aksoy DY, Kerimoglu U, Okur H, Canpinar H, Karaagaoglu E, Yetgin S, Kansu E, 
Gedik O. Effects of prophylactic thyroid  hormone  replacement  in euthyroid  
Hashimoto’s thyroiditis. Endocr J 2005; 52: 337-343. 
www.intechopen.com
 
Hashimoto's Thyroiditis in Children and Adolescents 
 
39 
[61] Hegedu’s  L,  Hansen  JM,  Feldt-Rasmussen  U,  Hansen  BM, Hoier-Madsen M. 
Influence of thyroxine treatment on thyroid size and anti-thyroid peroxidase 
antibodies in Hashimoto’s thyroiditis. Clin Endocrinol 1991; 35: 235-238. 
[62] Schmidt M, Voell M, Rahlff I, Dietlein M, Kobe C, Faust M, Schicha H. Long-term 
follow-up of antithyroid peroxidase antibodies in patients with chronic 
autoimmune thyroiditis (Hashimoto's thyroiditis) treated with levothyroxine. 
Thyroid 2008; 18: 755-760. 
[63] Pedersen  OM,  Aardal  NP,  Larssen  TB,  Varhaug  JE, Myking O, Vik-Mo H. The 
value of ultrasonography in predicting autoimmune thyroid disease.  Thyroid 2000; 
10: 251-259. 
[64] Schiemann  U,  Avenhaus  W,  Konturek  J,  Gellner  R, Hengst  K,  Gross  M.  Relation  
of  clinical  features  and laboratory parameters  to thyroid echogenicity  measured 
by  standardized  grey  scale  ultrasonography  in  patients with  Hashimoto's  
thyroiditis.  Med Sei Monit 2003; 9: 49-53. 
[65] Raber W, Gessl A, Nowotny P, Vierhapper H. Thyroid ultrasound   versus   antithyroid   
peroxidase   antibody determination:  a cohort study of four hundred fifty-one 
subjects. Thyroid 2002; 12: 725-731. 
[66] Loy  M,  Cianchietti  ME,  Cardia  F,  Melis  A,  Boi  F, Mariotti   S.  Correlation   of   
computerized   gray-scale sonographic findings with thyroid function and thyroid 
autoimmune activity in patients with Hashimoto's thyroiditis. J Clin Ultrasound 
2004; 32: 136-140. 
[67] Vlachopapadopoulou E, Thomas D, Karachaliou F, Chatzimarkou F, Memalai L, 
Vakaki M, Kaldrymides P, Michalacos S.  Evolution of Sonographic Appearance of 
the Thyroid Gland in Children with Hashimoto's Thyroiditis. Journal of Pediatric 
Endocrinology & Metabolism 2009; 22: 339-344. 
[68] Alos N, Huot C, Lambert R, Van Vliet G. Thyroid scintigraphy in children and 
adolescents with Hashimoto disease. J Pediatr 1995; 127: 951-953. 
[69] Hancock SL, McDougall IR, Constine LS. Thyroid abnormalities after therapeutic 
external radiation. Int J Radiat Oncol Biol Phys. 1995; 31: 1165-1170. 
[70] Bessho K, Etani Y, Ichimori H, Miyoshi Y, Namba N, Yoneda A, Ooue T, Chihara T, 
Morii E, Aoki T, Murakami M, Mushiake S, Ozono K. Increased type 3 
iodothyronine deiodinase activity in a regrown hepatic hemangioma with 
consumptive hypothyroidism. Eur J Pediatr. 2010; 169: 215-221. 
[71] Mandel SJ, Brent GA, Larsen PR. Levothyroxine therapy in patients with thyroid 
disease. Ann Intern Med 1993; 119: 492-502. 
[72] Van Dop C, Conte FA, Koch TK, Clark SJ, Wilson-Davis SL, Grumbach MM. 
Pseudotumor cerebri associated with initiation of levothyroxine therapy for 
juvenile hypothyroidism. N Engl J Med 1983; 308: 1076-1080. 
[73] Lafranchi S. Thyroiditis and acquired hypothyroidism. Pediatr Ann 1992; 21: 32-39. 
[74] Kuroiwa T, Okabe Y, Hasuo K, Yasumori K, Mizushima A, Masuda K. MR imaging of 
pituitary hypertrophy due to juvenile primary hypothyroidism: a case report. 
Clinical Imaging 1991; 15: 202–205. 
[75] Ahmed M, Banna M, Sakati N, Woodhouse N. Pituitary gland enlargement in primary 
hypothyroidism: a report of 5 cases with follow-up data. Hormone Research 1989; 
32: 188-192. 
www.intechopen.com
 
Autoimmune Disorders – Current Concepts and Advances from Bedside to Mechanistic Insights 
 
40
[76] Shih ML, Lee JA, Hsieh CB, Yu JC, Liu HD, Kebebew E, Clark OH, Duh QY.  
Thyroidectomy for Hashimoto’s thyroiditis: complications and associated cancers.  
Thyroid 2008; 18: 729-734. 
[77] Wormer BA, McHenry CR. Hashimoto’s thyroiditis: Outcome of surgical resection for 
patients with thyromegaly and compressive symptoms. The American Journal of 
Surgery 2011; 201: 416-419. 
[78] Radetti G, Gottardi E, Bona G, Corrias A, Salardi S, Loche S; Study Group for Thyroid 
Diseases of the Italian Society for Pediatric Endocrinology and Diabetes 
(SIEDP/ISPED). The natural history of euthyroid Hashimoto's thyroiditis in 
children. Journal of Pediatrics 2006; 149: 827-832. 
[79] Demirbilek H, Kandemir N, Gonc E.N, Ozon A, Alikasifoglu A. Assessment of thyroid 
function during the long course of Hashimoto’s thyroiditis in children and 
adolescents. Clinical Endocrinology 2009; 71: 451-454. 
[80] Gopalakrishnan S, Marwaha RK. Juvenile autoimmune thyroiditis. J Pediatr 
Endocrinol Metab 2007; 20: 961-970. 
[81] Gopalakrishnan PK, Chugh M, Chhillar VK, Ambardar MS, Sankar R. Goitrous 
autoimmune thyroiditis in a pediatric population: a longitudinal study. Pediatrics 
2008; 122: 670-674. 
[82] Jaruratanasirikul S, Leethanaporn K, Khuntigij P, Sriplung H. The clinical course of 
Hashimoto’s thyroiditis in children and adolescents: 6 years longitudinal follow-
up. Journal of Pediatric Endocrinology and Metabolism 2001; 14: 177-184. 
[83] Wasniewska M, Salerno M, Cassio A, Corrias A, Aversa T, Zirilli G, Capalbo D, Bal M, 
Mussa A, De Luca F. Prospective evaluation of the natural course of idiopathic 
subclinical hypothyroidism in childhood and adolescence. Eur J Endocrinol 2009; 
160: 417-421. 
[84] D´ıez JJ, Iglesias P. Spontaneous subclinical hypothyroidism in patients older than 55 
years: an analysis of natural course and risk factors for the development of overt 
thyroid failure. Journal of Clinical Endocrinology and Metabolism 2004; 89: 4890-
4897. 
[85] Yoshida H, Amino N, Yagawa K, Uemura K, Satoh M, Miyai K, Kumahara Y. 
Association of serum antithyroid antibodies with lymphocytic infiltration of the 
thyroid gland: studies of seventy autopsied cases. J Clin Endocrinol Metab 1978; 46: 
859-862. 
[86] Ikemoto K. A long-term follow-up study of patients with goitrous Hashimoto’s disease 
– prognosis and its predictive factors. Nippon Naibunpi Gakkai Zasshi 1990; 66: 
619-635. 
[87] Konno N, Makita H, Yuri K, Iizuka N, Kawasaki K. Association between dietary iodine 
intake and prevalence of subclinical hypothyroidism in the coastal regions of Japan. 
J Clin Endocrinol Metab 1994; 78: 393-397. 
[88] Yoon SJ, Choi SR, Kim DM, Kim JU, Kim KW, Ahn CW, Cha BS, Lim SK, Kim KR, Lee 
HC, Huh KB. The effect of iodine restriction on thyroid function in patients with 
hypothyroidism due to Hashimoto's thyroiditis. Yonsei Med J 2003; 44: 227-235. 
[89] Dunn JT, Semigran MJ, Delange F. The prevention and management of iodine-induced 
hyperthyroidism and its cardiac features. Thyroid 1998; 8: 101-106. 
[90] Robison LM, Sylvester PW, Birkenfeld P, Lang JP, Bull RJ. Comparison of the 
effects of iodine and iodide on thyroid function in humans. J Toxicol Environ 
Health A 1998; 55: 93-106. 
www.intechopen.com
Autoimmune Disorders - Current Concepts and Advances from
Bedside to Mechanistic Insights
Edited by Dr. Fang-Ping Huang
ISBN 978-953-307-653-9
Hard cover, 614 pages
Publisher InTech
Published online 14, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Autoimmune disorders are caused due to break down of the immune system, which consequently fails in its
ability to differentiate "self" from "non-self" in the context of immunology. The diseases are intriguing, both
clinically and immunologically, for their diversified clinical phenotypes and complex underlying immunological
mechanisms. This book offers cutting-edge information on some of the specific autoimmune disease
phenotypes, respective diagnostic and prognostic measures, classical and new therapeutic options currently
available, pathogenesis and underlying mechanisms potentially involved, and beyond. In the form of Open
Access, such information is made freely available to clinicians, basic scientists and many others who will be
interested regarding current advances in the areas. Its potential readers will find many of the chapters
containing in-depth analysis, interesting discussions and various thought-provoking novel ideas.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Erkan Sarı, Abdulbaki Karaoglu and Ediz Yes ̧ilkaya (2011). Hashimoto's Thyroiditis in Children and
Adolescents, Autoimmune Disorders - Current Concepts and Advances from Bedside to Mechanistic Insights,
Dr. Fang-Ping Huang (Ed.), ISBN: 978-953-307-653-9, InTech, Available from:
http://www.intechopen.com/books/autoimmune-disorders-current-concepts-and-advances-from-bedside-to-
mechanistic-insights/hashimoto-s-thyroiditis-in-children-and-adolescents
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
